| Retirado antes de empezar | Fase 3 | dimethyl fumarateEsclerosis multiple remitente-recurrente · Formas recurrentes de esclerosis multiple | ene 2027 (prevista) |
| Completado | no aplica | ZuranoloneA Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy | ago 2026 (real) |
| Completado | Fase 3 | Nusinersen · ONWARDAtrofia muscular espinal | jul 2026 (real) |
| Completado | Fase 1 | FelzartamabNefritis lupica | jun 2026 (real) |
| Completado | Fase 3 | BIIB111 · SOLSTICECoroideremia · Retinosis pigmentaria ligada al cromosoma X | jun 2026 (real) |
| Completado | Fase 1 | OmaveloxoloneVoluntarios sanos | may 2026 (real) |
| Completado | Fase 1 | LitifilimabVoluntarios sanos | mar 2026 (real) |
| Completado | Fase 2 | BIIB122 · LUMAEnfermedad de Parkinson | mar 2026 (real) |
| Completado | Fase 1 | [89Zr]Zr-DFO-DiranersenVoluntarios sanos | mar 2026 (real) |
| Completado | Fase 2 | BIIB091 · FUSIONFormas recurrentes de esclerosis multiple | feb 2026 (real) |
| Completado | Fase 1 | OmaveloxoloneVoluntario sano | oct 2025 (real) |
| Retirado antes de empezar | Fase 3 | BIIB074 · SURGE-1Neuralgia del trigemino | oct 2025 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 4 | Nusinersen · RESPONDAtrofia muscular espinal | oct 2025 (real) |
| Completado | Fase 1 | OmaveloxoloneVoluntarios sanos | ago 2025 (real) |
| Retirado antes de empezar | Fase 3 | BIIB074 · SURGE-2Neuralgia del trigemino | ago 2025 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 3 | dimethyl fumarate · CONNECTesclerosis multiple recurrente-remitente | jul 2025 (real) |
| Retirado antes de empezar | Fase 2 | BIIB131 · DAISYA Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well | jul 2025 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | no aplica | NatalizumabEsclerosis multiple | abr 2025 (real) |
| Completado | Fase 4 | Dimethyl fumarateEsclerosis multiple | mar 2025 (real) |
| Completado | Fase 1 | BIIB091Voluntarios sanos | mar 2025 (real) |
| Completado | Fase 1 | OmaveloxoloneVoluntarios sanos | mar 2025 (real) |
| Completado | Fase 1 | BIIB091Voluntario sano | feb 2025 (real) |
| Completado | Fase 2 | Nusinersen · NURTUREAtrofia muscular espinal | dic 2024 (real) |
| Completado | no aplica | A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsEsclerosis multiple remitente-recurrente | nov 2024 (real) |
| Interrumpido | Fase 2 | RTA 901 · CYPRESSA Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain | nov 2024 (real) |
| Completado | Fase 1 | ZuranoloneTrastorno depresivo mayor | oct 2024 (real) |
| Completado | Fase 1 | BIIB800Voluntario sano | sep 2024 (real) |
| Retirado antes de empezar | Fase 2 | BIIB061Esclerosis multiple recurrente | sep 2024 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 3 | Diroximel fumarateFormas recidivantes de esclerosis multiple | sep 2024 (real) |
| Interrumpido | Fase 1/2 | BIIB105 · ALSpireEsclerosis lateral amiotrofica | ago 2024 (real) |
| Interrumpido | Fase 3 | Aducanumab · ENVISIONEnfermedad de Alzheimer | ago 2024 (real) |
| Completado | Fase 3 | TofersenELA causada por mutacion de superoxido dismutasa 1 (SOD1) | ago 2024 (real) |
| Interrumpido | no aplica | Natalizumab · SATURATE-MSEsclerosis multiple | jul 2024 (real) |
| Interrumpido | Fase 3 | AducanumabEnfermedad de Alzheimer | jul 2024 (real) |
| Completado | Sin fase asignada | Virtual reality · REALITYVirtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy | jul 2024 (real) |
| Completado | Fase 1 | BIIB122Voluntarios sanos | jun 2024 (real) |
| Completado | Fase 1 | HIB210A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers | jun 2024 (real) |
| Completado | Fase 1 | [14C]-BIIB091 · Mass BalanceVoluntarios sanos | may 2024 (real) |
| Completado | no aplica | NatalizumabEsclerosis multiple remitente-recurrente (EMRR) | abr 2024 (real) |
| Completado | no aplica | Konectom platformA Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage | abr 2024 (real) |
| Completado | Fase 1 | BIIB107Voluntarios sanos | mar 2024 (real) |
| Completado | Fase 3 | Nusinersen · DEVOTEAtrofia Muscular Espinal | feb 2024 (real) |
| Interrumpido | Fase 3 | NatalizumabEsclerosis multiple recurrente-remitente | ene 2024 (real) |
| Completado | no aplica | TysabriTysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries | dic 2023 (real) |
| Completado | Fase 2 | MOR202 · NewPLACEGlomerulonefritis · Nefropatia membranosa · antiPLA2R positivo | dic 2023 (real) |
| Completado | no aplica | Nusinersen Sodium Injection · PANDANon-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection | nov 2023 (real) |
| Completado | no aplica | Tysabri · TOPEsclerosis multiple remitente-recurrente | nov 2023 (real) |
| Interrumpido | Fase 4 | NatalizumabEsclerosis multiple remitente-recurrente | oct 2023 (real) |
| Completado | no aplica | Natalizumab · TYPIFIStudy of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants | oct 2023 (real) |
| Interrumpido | no aplica | Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study | sep 2023 (real) |
| Interrumpido | no aplica | IntuitionAn Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging | sep 2023 (real) |
| Completado | Fase 1 | OmaveloxoloneA TQTc Study for Omaveloxolone | sep 2023 (real) |
| Completado | Fase 1 | OmaveloxoloneSujetos Adultos Sanos | ago 2023 (real) |
| Completado | no aplica | K1TeA Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy | ago 2023 (real) |
| Interrumpido | Fase 3 | Bardoxolone methyl · EAGLEenfermedades crónicas del riñón · síndrome de Alport · enfermedad renal poliquística autosómica dominante | ago 2023 (real) |
| Completado | Fase 3 | nusinersen · SHINEAtrofia Muscular Espinal | ago 2023 (real) |
| Interrumpido | Fase 3 | Bardoxolone methyl oral capsule · FALCONriflon poliquistica autonumica dominante · ADPKD | ago 2023 (real) |
| Interrumpido | Fase 3 | BIIB122 · LIGHTHOUSEEnfermedad de Parkinson | jul 2023 (real) |
| Interrumpido | Fase 1 | BIIB132A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 | jul 2023 (real) |
| Completado | Sin fase asignada | Konectom NMD Application · DigiNOAAtrofia muscular espinal | jul 2023 (real) |
| Completado | Fase 1 | BIIB113Voluntarios sanos | jul 2023 (real) |
| Completado | Fase 3 | SAGE-217trastorno depresivo mayor | jun 2023 (real) |
| Interrumpido | no aplica | Diroximel FumarateFormas recurrentes de EM | abr 2023 (real) |
| Interrumpido | no aplica | Diroximel Fumarate · EXPER-CA/ILExploring Diroximel Fumarate Real-world Experience in Canada and Israel | abr 2023 (real) |
| Completado | Fase 2 | Felzartamab · IGNAZClinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy | feb 2023 (real) |
| Completado | Fase 3 | NatalizumabEsclerosis multiple recurrente-remitente | ene 2023 (real) |
| Completado | no aplica | MS PATHS Normative Sub-StudyVoluntarios sanos | dic 2022 (real) |
| Completado | no aplica | XOLARISNatural History of the Progression of X-Linked Retinitis Pigmentosa | dic 2022 (real) |
| Interrumpido | no aplica | Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple SclerosisEsclerosis multiple | dic 2022 (real) |
| Completado | no aplica | dimethyl fumarate · ESTEEMEsclerosis multiple | oct 2022 (real) |
| Completado | no aplica | Dimethyl Fumarate · TEC-ADHEREEsclerosis multiple remitente-recurrente | sep 2022 (real) |
| Completado | Fase 1 | BIIB122Voluntarios sanos | sep 2022 (real) |
| Completado | Fase 1 | BIIB091Voluntarios sanos | sep 2022 (real) |
| Completado | Fase 1 | AducanumabVoluntarios sanos | jul 2022 (real) |
| Completado | Sin fase asignada | DigiTomsEsclerosis multiple | jul 2022 (real) |
| Interrumpido | Fase 3 | Dimethyl FumarateEsclerosis multiple recurrente-remitente | jul 2022 (real) |
| Completado | no aplica | Infliximab · PERFUSEArtritis reumatoide · Espondilitis anquilosante · Artritis psoriasica · Enfermedad de Crohn · Colitis ulcerosa | jun 2022 (real) |
| Completado | Fase 2 | BIIB111 · GEMINICoroideremia | jun 2022 (real) |
| Completado | Fase 1 | Diroximel fumarateVoluntarios sanos | jun 2022 (real) |
| Interrumpido | no aplica | An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US | may 2022 (real) |
| Interrumpido | Fase 1 | BIIB078Esclerosis lateral amiotrofica | may 2022 (real) |
| Completado | Fase 2 | BIIB104 · TALLYA Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | mar 2022 (real) |
| Completado | Fase 3 | SAGE-217Depresion posparto | mar 2022 (real) |
| Completado | no aplica | Dimethyl fumarateBiogen Multiple Sclerosis Pregnancy Exposure Registry | feb 2022 (real) |
| Completado | Fase 1 | BIIB104 Reference FormulationVoluntarios Sanos | ene 2022 (real) |
| Completado | Fase 1 | BIIB104Voluntario sano | ene 2022 (real) |
| Retirado antes de empezar | Fase 1 | BIIB095Voluntarios sanos · Neuropatias diabeticas | ene 2022 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | no aplica | peginterferon beta-1a · POPPlegridy Observational Program | ene 2022 (real) |
| Completado | Fase 1/2 | MOR202 · M-PLACETrial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | ene 2022 (real) |
| Completado | Fase 1 temprana | Angelman Syndrome (AS) Biomarker Study | ene 2022 (real) |
| Completado | no aplica | Adalimumab · PROPERA Real-world Study of Imraldi® Use | nov 2021 (real) |
| Completado | Fase 1 | BIIB078Esclerosis lateral amiotrofica | nov 2021 (real) |
| Completado | Fase 1 | [14C] BIIB122Voluntarios sanos | nov 2021 (real) |
| Completado | Fase 3 | SAGE-217Trastorno depresivo mayor | oct 2021 (real) |
| Completado | Fase 2 | Bardoxolone methyl oral capsule · MERLINEnfermedad renal cronica | oct 2021 (real) |
| Completado | no aplica | Interferon Beta TherapyEsclerosis multiple · Esclerosis multiple remitente-recurrente | oct 2021 (real) |
| Completado | no aplica | MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study | oct 2021 (real) |
| Completado | Fase 1 | AducanumabVoluntarios sanos | oct 2021 (real) |
| Completado | no aplica | A Study to Assess Choroideremia (CHM) Health OutcomesCoroideremia | sep 2021 (real) |
| Completado | Fase 1 | BIIB122Voluntarios sanos | sep 2021 (real) |
| Interrumpido | Fase 2 | BIIB092 · TANGOEnfermedad de Alzheimer | ago 2021 (real) |
| Completado | Fase 3 | Tofersen · VALOR (Part C)Esclerosis lateral amiotrofica | jul 2021 (real) |
| Completado | Fase 1 | BIIB100Esclerosis lateral amiotrofica | jun 2021 (real) |
| Completado | no aplica | Dimethyl fumarate · Lympho-TECEsclerosis multiple remitente-recurrente | jun 2021 (real) |
| Completado | Fase 1 | TofersenVoluntarios sanos | jun 2021 (real) |
| Completado | Fase 3 | ALKS 8700Esclerosis multiple | jun 2021 (real) |
| Completado | no aplica | Natural Disease Progression in Participants With Choroideremia | may 2021 (real) |
| Interrumpido | Fase 1 | BIIB054Enfermedad de Parkinson | abr 2021 (real) |
| Interrumpido | Fase 2 | BIIB074Neuropatia de fibra pequena · Diabetes mellitus | abr 2021 (real) |
| Completado | Fase 1 | BIIB133Voluntarios sanos | abr 2021 (real) |
| Completado | Fase 3 | SAGE-217Trastorno depresivo mayor | mar 2021 (real) |
| Interrumpido | Fase 2 | BIIB033 · AFFINITYEsclerosis multiple | feb 2021 (real) |
| Completado | Fase 1 | DNL151Enfermedad de Parkinson | dic 2020 (real) |
| Completado | Fase 3 | BIIB111 · STARCoroideremia | dic 2020 (real) |
| Completado | Fase 1/2 | BIIB112 · XIRIUSA Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 | nov 2020 (real) |
| Completado | Fase 1 | BIIB104Voluntarios sanos | nov 2020 (real) |
| Interrumpido | Fase 2 | BIIB054 · SPARKEnfermedad de Parkinson | oct 2020 (real) |
| Completado | Fase 4 | peginterferon beta-1a · PLENOEsclerosis multiple recurrente-remitente | oct 2020 (real) |
| Completado | Fase 2/3 | Bardoxolone Methyl · CARDINALsindrome de Alport | oct 2020 (real) |
| Completado | no aplica | NIGHTNatural History of the Progression of Choroideremia Study | oct 2020 (real) |
| Interrumpido | Fase 3 | Bardoxolone methyl · RANGERHipertension pulmonar | sep 2020 (real) |
| Interrumpido | Fase 3 | Bardoxolone methyl capsulesHipertension arterial pulmonar asociada a enfermedad del tejido conectivo | may 2020 (real) |
| Completado | no aplica | Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHSEsclerosis multiple | abr 2020 (real) |
| Interrumpido | Fase 1 | BIIB092Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 | mar 2020 (real) |
| Completado | Fase 1 | BIIB076Enfermedad de Alzheimer · Voluntarios sanos | mar 2020 (real) |
| Completado | Fase 1 | Omaveloxolone 50 mg capsulesInsuficiencia hepatica | ene 2020 (real) |
| Completado | Fase 2 | Natalizumab · OPUSEpilepsia, Crisis focales, Crisis parciales | ene 2020 (real) |
| Completado | Fase 1 | BIIB091Voluntarios sanos | ene 2020 (real) |
| Interrumpido | Fase 3 | SAGE-217Trastorno depresivo mayor | ene 2020 (real) |
| Completado | Fase 1 | BIIB104Voluntarios sanos | dic 2019 (real) |
| Interrumpido | Fase 3 | SAGE-217Trastorno depresivo mayor · Insomnio | dic 2019 (real) |
| Interrumpido | Fase 2 | BG00011 · SPIRITFibrosis pulmonar idiopatica | nov 2019 (real) |
| Completado | Fase 3 | dimethyl fumarate · ENDORSEesclerosis multiple recurrente-remitente | nov 2019 (real) |
| Completado | Fase 2 | Omaveloxolone CapsulesAtaxia de Friedreich | oct 2019 (real) |
| Completado | Fase 3 | SAGE-217trastorno depresivo mayor | sep 2019 (real) |
| Completado | no aplica | FORWARDCognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) | sep 2019 (real) |
| Interrumpido | Fase 2 | BIIB092 · PASSPORTStudy of BIIB092 in Participants With Progressive Supranuclear Palsy | sep 2019 (real) |
| Completado | Fase 2 | BIIB059 · LILACLupus eritematoso sistemico · Lupus eritematoso cutaneo activo | ago 2019 (real) |
| Completado | Fase 1 | OmaveloxoloneSujetos Adultos Sanos | ago 2019 (real) |
| Interrumpido | Fase 3 | Aducanumab · ENGAGEenfermedad de Alzheimer | ago 2019 (real) |
| Interrumpido | Fase 3 | Aducanumab · EMERGEenfermedad de Alzheimer | ago 2019 (real) |
| Interrumpido | Fase 1 | Aducanumab · PRIMEEnfermedad de Alzheimer | jul 2019 (real) |
| Completado | no aplica | SC Peginterferon beta-1a · PERFECTEsclerosis multiple remitente-recurrente | jul 2019 (real) |
| Interrumpido | Fase 2 | Aducanumab · EVOLVEDisfuncion cognitiva · Enfermedad de Alzheimer | jul 2019 (real) |
| Retirado antes de empezar | Fase 4 | dimethyl fumarate · PROMPTEsclerosis multiple remitente recurrente | jul 2019 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 1 | RTA 1701 capsulesSano | jun 2019 (real) |
| Completado | Fase 3 | ALKS 8700Esclerosis multiple remitente recurrente | jun 2019 (real) |
| Completado | Fase 1 | [14C]-OmaveloxoloneA Human AME Study for Omaveloxolone | may 2019 (real) |
| Completado | Fase 2 | SAGE-217Trastorno bipolar I · Trastorno bipolar II · Episodio depresivo mayor | may 2019 (real) |
| Completado | Fase 1 | BIIB095Voluntario sano | abr 2019 (real) |
| Completado | no aplica | Fampridine · LIBERATEEsclerosis multiple | feb 2019 (real) |
| Interrumpido | Fase 2 | BIIB074 · RELAY-1 ExtendExtension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 | feb 2019 (real) |
| Completado | Fase 2 | Bardoxolone methyl capsules · PHOENIXA Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | ene 2019 (real) |
| Completado | no aplica | Benepali · BENEFITObservational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel | nov 2018 (real) |
| Completado | no aplica | natalizumab · STRIVEEsclerosis multiple remitente-recurrente | nov 2018 (real) |
| Completado | Fase 1 | omaveloxoloneVoluntarios sanos | nov 2018 (real) |
| Completado | Fase 3 | SAGE-217 15Depresion posparto | nov 2018 (real) |
| Interrumpido | Fase 3 | BIIB019 · EXTENDEsclerosis multiple remitente-recurrente · Esclerosis multiple | sep 2018 (real) |
| Interrumpido | Fase 2 | Nusinersen · EMBRACEAtrofia muscular espinal | sep 2018 (real) |
| Completado | Fase 3 | dimethyl fumarateEsclerosis multiple remitente-recurrente | sep 2018 (real) |
| Interrumpido | Fase 3 | Daclizumab · SUSTAINEsclerosis multiple remitente-recurrente (EMRR) | sep 2018 (real) |
| Completado | Fase 2 | BIIB074 · RELAY-1Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy | ago 2018 (real) |
| Completado | no aplica | Methodology Study of Novel Outcome Measures to Assess Progression of ALSEsclerosis lateral amiotrofica | jul 2018 (real) |
| Completado | no aplica | BenepaliArtritis reumatoide · Espondiloartropatias | jun 2018 (real) |
| Completado | Fase 1 | BIIB059Voluntarios sanos | jun 2018 (real) |
| Completado | Fase 1/2 | Omaveloxolone CapsulesRTA 408 Capsules in Patients With Melanoma - REVEAL | may 2018 (real) |
| Completado | Fase 1 | BIIB074A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen | mar 2018 (real) |
| Completado | no aplica | natalizumab · PROTYSEsclerosis multiple | ene 2018 (real) |
| Completado | Fase 4 | VITALITYEsclerosis multiple remitente-recurrente | ene 2018 (real) |
| Completado | Fase 2 | Bardoxolone methylHipertension arterial pulmonar · Hipertension pulmonar · Enfermedad pulmonar intersticial · Neumonia intersticial idiopatica · Fibrosis pulmonar idiopatica · Sarcoidosis · Enfermedad pulmonar intersticial asociada a bronquiolitis respiratoria · Neumonia intersticial descamativa · Neumonia organizada criptogenica · Neumonitis intersticial aguda · Neumonia intersticial linfoide idiopatica · Fibroelastosis pleuroparenquimatosa idiopatica | ene 2018 (real) |
| Completado | no aplica | natalizumab · iTOPEsclerosis multiple remitente-recurrente | dic 2017 (real) |
| Completado | Fase 1 | SAGE-217 high doseVoluntarios sanos | dic 2017 (real) |
| Completado | Fase 2 | SAGE-217Temblor esencial | nov 2017 (real) |
| Completado | Fase 2 | natalizumab · ACTION2Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke | nov 2017 (real) |
| Completado | Fase 1 | BIIB054Enfermedad de Parkinson · Voluntarios sanos | nov 2017 (real) |
| Completado | Fase 1 | Bardoxolone methyl capsules 10…Voluntarios sanos | nov 2017 (real) |
| Completado | Fase 2 | Omaveloxolone capsulesMiopatias mitocondriales | nov 2017 (real) |
| Completado | Fase 1 | BIIB074Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 | oct 2017 (real) |
| Completado | Fase 2 | SAGE-217A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder | oct 2017 (real) |
| Completado | Fase 4 | peginterferon beta-1a · PLATINUMEsclerosis multiple remitente-recurrente (RRMS) | oct 2017 (real) |
| Retirado antes de empezar | Fase 4 | dimethyl fumarate · TECNERGYEsclerosis múltiple remitente-recurrente · Esclerosis múltiple | oct 2017 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 2 | SAGE-217Enfermedad de Parkinson | sep 2017 (real) |
| Completado | no aplica | A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome | ago 2017 (real) |
| Completado | Fase 2 | nusinersenAtrofia muscular espinal | ago 2017 (real) |
| Completado | Fase 1 | RTA 901 CapsulesVoluntarios sanos | jul 2017 (real) |
| Completado | Fase 4 | dimethyl fumarate · TECONGUTEsclerosis multiple remitente-recurrente | jun 2017 (real) |
| Completado | no aplica | Scan-Rescan Sub-Study of MS PATHSEsclerosis multiple | may 2017 (real) |
| Completado | Fase 3 | dimethyl fumarateEsclerosis multiple recurrente-remitente · Esclerosis multiple | abr 2017 (real) |
| Completado | Fase 2 | BG00011Fibrosis pulmonar idiopatica (IPF) | mar 2017 (real) |
| Completado | no aplica | dimethyl fumarateEsclerosis multiple | mar 2017 (real) |
| Retirado antes de empezar | no aplica | Systemic Sclerosis Clinical and Biomarker StudyVoluntarios sanos · Esclerosis sistemica | mar 2017 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 3 | Nusinersen · CHERISHAtrofia muscular espinal | feb 2017 (real) |
| Completado | Fase 4 | dimethyl fumarate · MITIGATEEsclerosis multiple | feb 2017 (real) |
| Completado | Fase 1 | BIIB074 Treatment ANew Formulation and Food Effect Study of BIIB074 | feb 2017 (real) |
| Retirado antes de empezar | Fase 4 | Interferon Beta · FrequencyEsclerosis multiple recurrente | feb 2017 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 1 | BIIB074PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants | feb 2017 (real) |
| Completado | Fase 1 | nusinersenAtrofia muscular espinal | ene 2017 (real) |
| Completado | Fase 2 | BIIB033 100mg · RENEWEDLong-Term Assessment of Remyelinating Therapy | ene 2017 (real) |
| Completado | Fase 1 | BIIB118Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers | ene 2017 (real) |
| Completado | Fase 2 | BIIB074Eritromelalgia primaria hereditaria | dic 2016 (real) |
| Completado | Fase 3 | dimethyl fumarate · StarTecesclerosis multiple recurrente-remitente | dic 2016 (real) |
| Completado | Fase 1 | Aducanumab · PROPELEnfermedad de Alzheimer | dic 2016 (real) |
| Interrumpido | no aplica | CHAMPIONS CONTEsclerosis multiple | dic 2016 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | no aplica | EFFECTEsclerosis multiple | dic 2016 (real) |
| Completado | Fase 1 | BIIB068A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants | dic 2016 (real) |
| Interrumpido | Fase 3 | nusinersen · ENDEARAtrofia muscular espinal | nov 2016 (real) |
| Completado | Fase 1 | aducanumabEnfermedad de Alzheimer | nov 2016 (real) |
| Completado | Fase 1 | BIIB033Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes | nov 2016 (real) |
| Completado | Fase 1 | BIIB092 · CN002-003Paralisis supranuclear progresiva | oct 2016 (real) |
| Interrumpido | Fase 2 | PF-04958242A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | sep 2016 (real) |
| Completado | Fase 2 | dimethyl fumarate · FOCUSEsclerosis multiple remitente-recurrente | sep 2016 (real) |
| Completado | Fase 1 | BIIB033Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants | sep 2016 (real) |
| Completado | Fase 2 | BIIB019 · SELECTEDEsclerosis multiple remitente-recurrente | ago 2016 (real) |
| Completado | no aplica | natalizumabEsclerosis multiple remitente-recurrente | ago 2016 (real) |
| Completado | Fase 1 | CNV1014802Voluntarios sanos | ago 2016 (real) |
| Retirado antes de empezar | Fase 4 | peginterferon beta-1a · BRITEesclerosis multiple remitente-recurrente (RRMS) | ago 2016 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | no aplica | Pilot Tape Harvesting StudyDermatitis atopica · Sano · Lupus eritematoso discoide · Lupus eritematoso cutaneo subagudo | ago 2016 (real) |
| Interrumpido | Fase 1 | BIIB063Voluntarios sanos | jun 2016 (real) |
| Completado | Fase 1 | BIIB059Lupus eritematoso sistemico · Voluntarios sanos | may 2016 (real) |
| Interrumpido | Fase 4 | natalizumab · REVEALEsclerosis multiple remitente-recurrente | may 2016 (real) |
| Completado | Fase 2 | dimethyl fumarateVaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. | may 2016 (real) |
| Interrumpido | Fase 4 | natalizumab · ESCALATEesclerosis multiple recurrente-remitente | may 2016 (real) |
| Completado | Fase 1 | BIIB074Dolor neuropatico | may 2016 (real) |
| Completado | Fase 1 | BIIB061Voluntarios sanos | may 2016 (real) |
| Completado | Fase 1 | BMS-986168Tauopatias | abr 2016 (real) |
| Interrumpido | Fase 4 | dimethyl fumarateEsclerosis multiple | abr 2016 (real) |
| Completado | no aplica | MSPTEsclerosis multiple | abr 2016 (real) |
| Completado | Fase 1 | BIIB074Dolor neuropatico | abr 2016 (real) |
| Completado | Fase 4 | dimethyl fumarate · PROTECEsclerosis multiple remitente-recurrente · Esclerosis multiple | mar 2016 (real) |
| Interrumpido | no aplica | dimethyl fumarate · IMPROVEEsclerosis multiple remitente-recurrente | mar 2016 (real) |
| Interrumpido | no aplica | FampridineFampridine Pregnancy Exposure Registry | feb 2016 (real) |
| Completado | no aplica | dimethyl fumarate · REALIZEEsclerosis multiple | feb 2016 (real) |
| Completado | no aplica | interferon beta-1a · SFERAEsclerosis Multiple Remitente-Recurrente · Sindrome Clinico Aislado (CIS) · Esclerosis Multiple | feb 2016 (real) |
| Completado | no aplica | dimethyl fumarate · RESPONDEffectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS | feb 2016 (real) |
| Completado | Fase 3 | fampridine · ENHANCEEsclerosis multiple | feb 2016 (real) |
| Completado | Fase 4 | dimethyl fumarate · TOLERATEesclerosis multiple remitente-recurrente | feb 2016 (real) |
| Interrumpido | Fase 2 | BIIB023Nefritis lupica | ene 2016 (real) |
| Completado | Fase 3 | Midazolam · OBSERVEesclerosis multiple remitente-recurrente | ene 2016 (real) |
| Interrumpido | Fase 3 | dimethyl fumarate · INSPIREEsclerosis multiple secundaria progresiva | ene 2016 (real) |
| Interrumpido | Fase 3 | dimethyl fumarate · TITRATIONEsclerosis multiple | dic 2015 (real) |
| Interrumpido | Fase 2 | BIIB023 · ATLASNefritis lupica | dic 2015 (real) |
| Completado | Fase 2 | BIIB033 · SYNERGYEsclerosis multiple | dic 2015 (real) |
| Completado | no aplica | natalizumab · STRATIFY-2Esclerosis Multiple Recurrente | nov 2015 (real) |
| Completado | Fase 1 | BIIB118Sano | oct 2015 (real) |
| Interrumpido | no aplica | COSTANEsclerosis multiple remitente-recurrente | oct 2015 (real) |
| Completado | Fase 1 | omaveloxolone · DISCOVERRTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | oct 2015 (real) |
| Completado | no aplica | natalizumabEsclerosis multiple | oct 2015 (real) |
| Completado | Fase 3 | peginterferon beta-1a · ATTAINEsclerosis multiple recurrente | oct 2015 (real) |
| Completado | Fase 3 | BIIB017 · ALLOWEsclerosis multiple recurrente | oct 2015 (real) |
| Completado | Fase 3 | BIIB041 · MOTION - JAPANEsclerosis multiple, remitente progresiva · Esclerosis multiple primaria progresiva · Esclerosis multiple remitente-recurrente · Esclerosis multiple secundaria progresiva · Esclerosis multiple | oct 2015 (real) |
| Completado | no aplica | Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment BatterySano | ago 2015 (real) |
| Completado | Fase 1 | BIIB061Esclerosis multiple | ago 2015 (real) |
| Interrumpido | Fase 3 | natalizumab · ASCEND in SPMSEsclerosis multiple secundaria progresiva | jul 2015 (real) |
| Completado | Fase 3 | dimethyl fumarateEsclerosis multiple remitente-recurrente · Esclerosis multiple | jun 2015 (real) |
| Interrumpido | Fase 2 | natalizumab · SIMPLIFYEsclerosis multiple recurrente | jun 2015 (real) |
| Interrumpido | no aplica | natalizumab · INFORMEnfermedad de Crohn | may 2015 (real) |
| Completado | no aplica | TYGRISEsclerosis multiple | may 2015 (real) |
| Completado | Fase 2 | Omaveloxolone Lotion 0.5%Cancer de mama | abr 2015 (real) |
| Completado | Fase 1 | CNV1014802PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers | abr 2015 (real) |
| Completado | Fase 1 | PF-04958242 · MADEsquizofrenia | abr 2015 (real) |
| Completado | Fase 1 | PF-04958242Voluntarios sanos | mar 2015 (real) |
| Completado | Fase 2 | BG00010 · SPRINTBG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy | mar 2015 (real) |
| Completado | no aplica | Functional MRI in Lupus NephritisSano · Nefritis lupica | mar 2015 (real) |
| Completado | Fase 2 | Omaveloxolone Ophthalmic…RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD | feb 2015 (real) |
| Completado | Fase 2 | natalizumab · ACTIONEffect of Natalizumab on Infarct Volume in Acute Ischemic Stroke | feb 2015 (real) |
| Completado | Fase 4 | dimethyl fumarate · ASSUREesclerosis multiple recurrente-remitente | feb 2015 (real) |
| Completado | Fase 1/2 | NusinersenAtrofia muscular espinal | ene 2015 (real) |
| Completado | no aplica | natalizumab · STRATEGYEsclerosis multiple remitente-recurrente | ene 2015 (real) |
| Completado | Fase 1 | Study DrugEsclerosis multiple | dic 2014 (real) |
| Completado | Fase 1 | peginterferon beta-1aEsclerosis multiple | dic 2014 (real) |
| Completado | Fase 2 | natalizumabEsclerosis multiple remitente-recurrente | dic 2014 (real) |
| Completado | Fase 1 | PF-04958242Sano | nov 2014 (real) |
| Completado | no aplica | TYGRIS - ROWEsclerosis multiple | nov 2014 (real) |
| Completado | Fase 2 | BIIB033BIIB033 In Acute Optic Neuritis (AON) | oct 2014 (real) |
| Completado | no aplica | CAPPSEsclerosis multiple | oct 2014 (real) |
| Completado | Fase 2 | Omaveloxolone Ophthalmic…Inflamacion y dolor tras cirugia ocular | sep 2014 (real) |
| Completado | Fase 1 | NatalizumabEsclerosis multiple remitente-recurrente | sep 2014 (real) |
| Completado | no aplica | Interferon beta-1a · AVAILEsclerosis multiple | sep 2014 (real) |
| Completado | Fase 1 | BIIB061Voluntarios sanos | sep 2014 (real) |
| Interrumpido | no aplica | Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal LeukoencephalopathyLeucoencefalopatia multifocal progresiva | ago 2014 (real) |
| Completado | Fase 1 | BG00010 IVRadiculopatia lumbar dolorosa · Sano | ago 2014 (real) |
| Completado | Fase 1 | dimethyl fumarateVoluntarios sanos | jul 2014 (real) |
| Completado | Fase 1 | RTA 408 Lotion 0.5%Voluntarios sanos | abr 2014 (real) |
| Completado | Fase 2 | natalizumab IV · REFINEEsclerosis multiple remitente-recurrente | abr 2014 (real) |
| Completado | Fase 1 | dimethyl fumarateVoluntarios sanos | abr 2014 (real) |
| Interrumpido | Fase 3 | Natalizumab · STRATAesclerosis multiple remitente-recurrente | abr 2014 (real) |
| Completado | Fase 2 | CNV1014802A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia | mar 2014 (real) |
| Completado | Fase 3 | BIIB019 · (DECIDE)Esclerosis multiple remitente-recurrente | mar 2014 (real) |
| Completado | Fase 1 | BIIB019 subcutaneous injectionVoluntarios sanos | mar 2014 (real) |
| Completado | Fase 1 | nusinersenAtrofia muscular espinal | feb 2014 (real) |
| Completado | Fase 1 | Peginterferon Beta-1aVoluntarios sanos | feb 2014 (real) |
| Completado | Fase 1 | PF-04958242Esquizofrenia | feb 2014 (real) |
| Retirado antes de empezar | Fase 2 | BIIB057 · EMBRACEArtritis reumatoide | feb 2014 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 1 | BIIB023Voluntarios sanos | ene 2014 (real) |
| Completado | no aplica | ACTIMSA Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis | ene 2014 (real) |
| Completado | Fase 4 | BG00002Esclerosis multiple remitente-recurrente | dic 2013 (real) |
| Completado | Fase 1 | bismuth subsalicylateSano | dic 2013 (real) |
| Completado | Fase 4 | BG00012 · MANAGEFormas recurrentes de esclerosis multiple | nov 2013 (real) |
| Completado | no aplica | PERSISTEsclerosis multiple | sep 2013 (real) |
| Completado | Fase 2 | BIIB041 · MOBILEEsclerosis multiple | ago 2013 (real) |
| Completado | Fase 1 | BIIB037Enfermedad de Alzheimer | ago 2013 (real) |
| Completado | Fase 4 | Fampridine · ENABLEEsclerosis multiple | jul 2013 (real) |
| Completado | no aplica | BATTER-UPBiomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients | jul 2013 (real) |
| Completado | Fase 1 | PF-04958242A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss | feb 2013 (real) |
| Completado | Fase 1 | nusinersen · SMNRxAtrofia muscular espinal | ene 2013 (real) |
| Completado | Fase 1 | PF-04958242Voluntario sano | dic 2012 (real) |
| Interrumpido | Fase 1 | Bardoxolone MethylPharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes | nov 2012 (real) |
| Completado | Fase 1 | Bardoxolone Methyl 20mgVoluntarios sanos | nov 2012 (real) |
| Completado | Fase 1 | Bardoxolone MethylInsuficiencia hepatica · Voluntarios sanos | nov 2012 (real) |
| Retirado antes de empezar | Fase 1 | Bardoxolone MethylPilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes | nov 2012 (real) |
| Interrumpido | Fase 1 | 20 mg bardoxolone methylEnfermedad renal cronica · Diabetes tipo 2 | nov 2012 (real) |
| Retirado antes de empezar | Fase 2 | Bardoxolone MethylA Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus | oct 2012 (real) |
| Retirado antes de empezar | Fase 2 | Bardoxolone Methyl 20 mgEnfermedad renal en etapa terminal · Diabetes mellitus tipo 2 | oct 2012 (real) |
| Interrumpido | Fase 3 | Bardoxolone Methyl: 20 mg · BEACONInsuficiencia renal crónica · Diabetes mellitus tipo 2 | oct 2012 (real) |
| Completado | Fase 3 | BIIB017 · ADVANCEEsclerosis multiple recurrente | oct 2012 (real) |
| Completado | Fase 3 | BG00012Sano | oct 2012 (real) |
| Completado | Fase 1 | BIIB017Voluntarios sanos · Esclerosis multiple | oct 2012 (real) |
| Completado | Fase 1 | Test productVoluntarios sanos | sep 2012 (real) |
| Completado | Fase 1 | BG00010Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica. | sep 2012 (real) |
| Completado | Fase 1 | PF-04958242 capsuleSanos | sep 2012 (real) |
| Completado | Fase 2/3 | Natalizumab · Tysabri JapanEsclerosis múltiple | ago 2012 (real) |
| Completado | Fase 1 | DigoxinVoluntarios sanos | jul 2012 (real) |
| Completado | Fase 4 | BG00002 · TIMEREsclerosis múltiple remitente-recurrente (RRMS) | jul 2012 (real) |
| Completado | no aplica | Pregnancy Exposure Registry for Tysabri® | jul 2012 (real) |
| Completado | Fase 2 | CNV1014802Radiculopatia lumbosacra | jun 2012 (real) |
| Completado | Fase 3 | BIIB041esclerosis multiple | jun 2012 (real) |
| Completado | no aplica | Tysabri® · STRATIFY-1Esclerosis multiple | jun 2012 (real) |
| Completado | no aplica | ASPECTEsclerosis multiple | may 2012 (real) |
| Completado | Fase 2 | BIIB019 · SELECTIONEsclerosis multiple remitente-recurrente | may 2012 (real) |
| Completado | no aplica | JEMSEsclerosis multiple | may 2012 (real) |
| Completado | Fase 1 | Interferon beta-1aEsclerosis multiple | abr 2012 (real) |
| Completado | Fase 1 | BG00012 Dose 1 · 109HV108Sano | abr 2012 (real) |
| Interrumpido | Fase 3 | BG00002 · SURPASSesclerosis multiple recurrente remitente | abr 2012 (real) |
| Completado | Fase 1 | BIIB033Esclerosis multiple remitente-recurrente | abr 2012 (real) |
| Completado | Fase 1 | PF-04958242Esquizofrenia | mar 2012 (real) |
| Completado | Fase 2 | dimethyl fumarate · EXPLOREEsclerosis multiple remitente-recurrente | mar 2012 (real) |
| Completado | Fase 1 | BG00010Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants | feb 2012 (real) |
| Interrumpido | Fase 4 | Methylprednisolone · IRISSindrome inflamatorio de reconstitucion inmune · Leucoencefalopatia multifocal progresiva | feb 2012 (real) |
| Completado | Fase 1 | BIIB023Voluntarios sanos | feb 2012 (real) |
| Completado | Fase 1 | bardoxolone methylVoluntarios sanos | dic 2011 (real) |
| Completado | Fase 1 | bardoxolone methylVoluntarios sanos | dic 2011 (real) |
| Completado | no aplica | COMPASSEsclerosis multiple remitente-recurrente | dic 2011 (real) |
| Completado | Fase 1 | PF-04958242Esquizofrenia | nov 2011 (real) |
| Completado | Fase 1 | natalizumabSafety Study of Natalizumab to Treat Multiple Sclerosis (MS) | nov 2011 (real) |
| Completado | Fase 2 | natalizumab · RESTORETreatment Interruption of Natalizumab | nov 2011 (real) |
| Completado | Fase 4 | Blood Sample · MATRIXEsclerosis multiple | oct 2011 (real) |
| Completado | Fase 2 | BIIB021Cancer de mama | oct 2011 (real) |
| Completado | Fase 1 | BIIB033Sano | oct 2011 (real) |
| Completado | Fase 3 | Avonex · Avonex ChinaEsclerosis multiple | oct 2011 (real) |
| Completado | Fase 1 | AvonexVoluntarios sanos | oct 2011 (real) |
| Completado | Fase 1 | BIIB028Tumor solido avanzado | oct 2011 (real) |
| Completado | Fase 1 | BIIB022 With Paclitaxel and…Cancer de pulmon no microcitico | sep 2011 (real) |
| Completado | Fase 1 | ExperimentalVoluntarios sanos | sep 2011 (real) |
| Completado | no aplica | BG9418Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) | sep 2011 (real) |
| Completado | Fase 3 | BG00012 · CONFIRMEsclerosis Multiple Remitente-Recurrente | ago 2011 (real) |
| Completado | Fase 1 | BIIB017A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers | ago 2011 (real) |
| Completado | no aplica | TYNERGYEffects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS | jun 2011 (real) |
| Completado | Fase 1 | BIIB015Tumor solido | jun 2011 (real) |
| Interrumpido | Fase 1 | PF-04958242Voluntarios sanos | may 2011 (real) |
| Completado | Fase 2 | BIIB019 · SELECTEsclerosis multiple remitente-recurrente | may 2011 (real) |
| Completado | Fase 1 | BIIB023Artritis reumatoide | abr 2011 (real) |
| Interrumpido | Fase 1 | 25G x 1" Needle AutoinjectorVoluntarios sanos | abr 2011 (real) |
| Completado | Fase 1 | BIIB022Carcinoma hepatocelular | abr 2011 (real) |
| Completado | Fase 1 | CNF2024Cancer de mama | abr 2011 (real) |
| Completado | Fase 1 | Dimethyl Fumarate · 109HV106Voluntarios sanos | mar 2011 (real) |
| Completado | no aplica | BG0002 · TRUSTEsclerosis multiple remitente-recurrente | mar 2011 (real) |
| Completado | Fase 3 | BG00012 · DEFINEEsclerosis multiple remitente-recurrente | feb 2011 (real) |
| Completado | Fase 2 | Bardoxolone methylPhase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | dic 2010 (real) |
| Interrumpido | Fase 1 | GaliximabMechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | nov 2010 (real) |
| Completado | Fase 1 | BIIB041Voluntarios sanos | nov 2010 (real) |
| Interrumpido | Fase 1/2 | mefloquineStudy to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | nov 2010 (real) |
| Completado | Fase 1 | AvonexVoluntarios sanos | oct 2010 (real) |
| Completado | Fase 1 | PF-04958242Voluntario sano | oct 2010 (real) |
| Completado | Fase 1 | BIIB021 and FoodTumor solido avanzado | ago 2010 (real) |
| Completado | no aplica | ENER-GEsclerosis multiple | jul 2010 (real) |
| Completado | Fase 1 | BIIB021Tumor solido avanzado | jul 2010 (real) |
| Interrumpido | Fase 2 | FCR + Lumiliximab · LUCIDLeucemia linfocitica cronica | jul 2010 (real) |
| Completado | Fase 3 | single-use autoinjector with a…esclerosis multiple | jul 2010 (real) |
| Completado | Fase 1 | BIIB014Voluntarios sanos | jun 2010 (real) |
| Interrumpido | Fase 2 | Lumiliximab + FCRLeucemia linfocitica cronica | jun 2010 (real) |
| Completado | Fase 2 | Bardoxolone MethylTrial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease | may 2010 (real) |
| Completado | Fase 1 | Glyburide for InjectionLesion Cerebral Traumatica · Accidente Cerebrovascular | may 2010 (real) |
| Retirado antes de empezar | Fase 4 | natalizumabEnfermedad de Crohn | may 2010 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 4 | Interferon-beta-1a · SIMCOMBINEsclerosis multiple | abr 2010 (real) |
| Completado | Fase 2 | BIIB021An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) | abr 2010 (real) |
| Completado | Fase 1 | BIIB014 50mgVoluntarios sanos | abr 2010 (real) |
| Completado | Fase 1 | BIIB022Tumor solido | abr 2010 (real) |
| Completado | Fase 2 | BG9418A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis | mar 2010 (real) |
| Completado | Fase 2 | BG00012Artritis reumatoide | feb 2010 (real) |
| Completado | Fase 1/2 | Lumiliximab with FCRLeucemia linfocitica cronica | ene 2010 (real) |
| Interrumpido | Fase 2 | Tonapofylline · POSEIDONInsuficiencia renal · Insuficiencia cardiaca | ene 2010 (real) |
| Interrumpido | Fase 3 | Galiximab in combination with…Linfoma no Hodgkin | ene 2010 (real) |
| Interrumpido | Fase 3 | galiximab in combination with…Linfoma no hodgkiniano | ene 2010 (real) |
| Completado | Fase 1 | GSK1014802Voluntarios sanos | dic 2009 (real) |
| Interrumpido | Fase 1/2 | BG00002Mieloma multiple | dic 2009 (real) |
| Completado | Fase 4 | Interferon-beta-1a · RENeuEsclerosis multiple remitente-recurrente | dic 2009 (real) |
| Interrumpido | Fase 1 | GSK1014802 low doseDolor Neuropatico · Dolor Neuropatico | nov 2009 (real) |
| Interrumpido | Fase 1 | Bardoxolone methylStudy With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer | nov 2009 (real) |
| Completado | Fase 4 | BG00002Esclerosis multiple | nov 2009 (real) |
| Completado | Fase 1 | BG00012A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS | oct 2009 (real) |
| Completado | Fase 3 | tonapofylline · TRIDENT-1Insuficiencia renal · Insuficiencia cardiaca congestiva | oct 2009 (real) |
| Completado | Fase 1 | BG00012Sano | oct 2009 (real) |
| Retirado antes de empezar | Fase 4 | TYSABRI and AVONEX · PRTOECTEsclerosis multiple recurrente-remitente | ago 2009 (prevista, ya pasada: sin actualizar en el registro) |
| Completado | Fase 1 | BG9928Insuficiencia hepatica | ago 2009 (real) |
| Completado | Fase 2 | RTA 402Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy | may 2009 (real) |
| Interrumpido | Fase 2 | IDEC-C2B8Artritis reumatoide | abr 2009 (real) |
| Completado | Fase 2 | BIIB014Enfermedad de Parkinson | abr 2009 (real) |
| Interrumpido | Fase 3 | BG9418Esclerosis multiple | feb 2009 (real) |
| Completado | Fase 1 | GSK1014802Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. | dic 2008 (real) |
| Completado | Fase 1 | RTA 744Glioma | dic 2008 (real) |
| Interrumpido | Fase 1 | RTA 744 · LMDA Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis | dic 2008 (real) |
| Interrumpido | Fase 2 | berubicin hydrochlorideRTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases | dic 2008 (real) |
| Completado | Fase 1 | Bardoxolone methylRTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | dic 2008 (real) |
| Completado | Fase 4 | NatalizumabEsclerosis multiple | dic 2008 (real) |
| Completado | no aplica | CylexEsclerosis multiple | dic 2008 (real) |
| Completado | Fase 2 | BIIB014 · MOBILEEnfermedad de Parkinson | dic 2008 (real) |
| Completado | Fase 4 | Interferon-beta-1aEsclerosis multiple remitente-recurrente | nov 2008 (real) |
| Interrumpido | Fase 2 | BG9924Artritis Reumatoide | oct 2008 (real) |
| Completado | Fase 2 | Baminercept alfa 1 · RESPONDArtritis reumatoide | oct 2008 (real) |
| Interrumpido | Fase 2 | Baminercept alfa · RESPOND-EXTArtritis reumatoide | oct 2008 (real) |
| Interrumpido | Fase 2 | BG9924Artritis reumatoide | oct 2008 (real) |
| Interrumpido | Fase 1 | CNF2024Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | jul 2008 (real) |
| Completado | Fase 1 | CNF2024Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | jul 2008 (real) |
| Completado | Fase 1 | GSK drugGSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers | may 2008 (real) |
| Completado | Fase 1 | BIIB017Sano | may 2008 (real) |
| Completado | Fase 1 | BIIB014Voluntarios sanos | abr 2008 (real) |
| Interrumpido | Fase 4 | Interferon beta-1a · TODAYEsclerosis multiple remitente-recurrente | feb 2008 (real) |
| Completado | Fase 3 | BG00002Esclerosis multiple remitente-recurrente | dic 2007 (real) |
| Interrumpido | Fase 1/2 | RTA 402Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction | nov 2007 (real) |
| Completado | Fase 2 | BG00002-EEsclerosis multiple | oct 2007 (real) |
| Completado | Fase 1 temprana | natalizumab treatmentFormas recurrentes de esclerosis multiple | oct 2007 (real) |
| Completado | no aplica | FITEsclerosis multiple remitente-recurrente | oct 2007 (real) |
| Completado | Fase 4 | rituximabLinfoma no Hodgkin | jun 2007 (real) |
| Completado | Fase 2 | BG9924Artritis reumatoide | may 2007 (real) |
| Completado | Fase 4 | Interferon-beta-1a · RECOVEREsclerosis multiple remitente-recurrente | ago 2006 (real) |
| Interrumpido | Fase 1 | hCBE-11Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors | ago 2006 (real) |
| Completado | Fase 4 | MethotrexateEsclerosis multiple remitente-recurrente | jun 2006 (real) |
| Completado | Fase 4 | SAFEEsclerosis multiple | may 2006 (real) |
| Completado | Fase 3 | Interferon beta-1aEsclerosis multiple | abr 2006 (real) |
| Completado | Fase 2 | BG00012Esclerosis multiple | mar 2006 (real) |
| Completado | Fase 2 | Interferon Beta-1aPolirradiculoneuropatia desmielinizante inflamatoria cronica | feb 2006 (real) |
| Interrumpido | Fase 1/2 | Unconjugated IDEC-159Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma | ene 2006 (real) |
| Completado | Fase 3 | NatalizumabEsclerosis multiple | oct 2005 (real) |
| Completado | Fase 3 | NatalizumabEsclerosis multiple, remitente-recurrente | abr 2005 (real) |
| Completado | Fase 3 | natalizumabEnfermedad de Crohn | mar 2005 (real) |
| Interrumpido | Fase 2 | natalizumabArtritis reumatoide | feb 2005 (real) |
| Interrumpido | Fase 2 | natalizumabArtritis reumatoide | feb 2005 (real) |
| Completado | Fase 2 | Interferon beta-1aEsclerosis multiple | dic 2004 (real) |
| Completado | Fase 3 | Natalizumabesclerosis multiple, forma recurrente-remitente | nov 2004 (real) |
| Completado | Fase 4 | natalizumabEnfermedad de Crohn | sep 2004 (real) |
| Completado | Fase 2 | natalizumabEnfermedad de Crohn | may 2004 (real) |
| Completado | Fase 1 | IDEC-152Leucemia linfocitica cronica | abr 2004 (real) |
| Completado | Fase 1/2 | IDEC-114Linfoma no Hodgkin | mar 2004 (real) |
| Completado | Fase 3 | natalizumabEnfermedad de Crohn | mar 2004 (real) |
| Completado | Fase 2 | NatalizumabEsclerosis multiple remitente-recurrente | mar 2004 (real) |
| Completado | Fase 3 | natalizumabEnfermedad de Crohn | sep 2003 (real) |
| Completado | Fase 2 | natalizumabEnfermedad de Crohn | jul 2003 (real) |
| Completado | Fase 4 | Interferon beta-1aesclerosis multiple | jun 2003 (real) |
| Completado | Fase 1/2 | IDEC-114Linfoma no Hodgkin | sep 2002 (real) |
| Completado | Fase 1 | Serum containing AvonexEsclerosis multiple | sin fecha |
| Completado | no aplica | 15yASSURANCEEsclerosis multiple | sin fecha |
| Retirado antes de empezar | Fase 1/2 | BaminerceptEsclerosis multiple secundaria progresiva | sin fecha |
| Completado | Fase 4 | Interferon beta-1a · FLAIREsclerosis multiple remitente-recurrente | sin fecha |
| Interrumpido | Fase 1 | CNF1010Leucemia linfocitica cronica | sin fecha |
| Completado | Fase 3 | rituximabLinfoma no Hodgkin de celulas B de bajo grado o folicular | sin fecha |
| Completado | Fase 4 | ibritumomab tiuxetanLinfoma No Hodgkin · Linfoma de Bajo Grado | sin fecha |
| Completado | no aplica | Interferon beta-1a · PROOFEsclerosis multiple | sin fecha |
| Completado | Fase 1/2 | Ad.hIFN-βInterferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases | sin fecha |
| Interrumpido | Fase 3 | ZevalinLinfoma no Hodgkin | sin fecha |
| Aprobado para comercializar | no aplica | TofersenEsclerosis lateral amiotrofica por superoxido dismutasa 1 | sin fecha |
| Ya no disponible | no aplica | NusinersenExpanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA) | sin fecha |
| Retirado antes de empezar | Fase 2 | active drugEnfermedad de Parkinson | sin fecha |
| Completado | Fase 4 | Interferon beta-1aEsclerosis multiple | sin fecha |
| Retirado antes de empezar | Fase 2 | RTA 402 Dose1Melanoma maligno | sin fecha |
| Ya no disponible | no aplica | omaveloxoloneMelanoma | sin fecha |
| Completado | Fase 3 | AlefaceptPsoriasis en placas cronica | sin fecha |
| Completado | Fase 1 | Interferon-betaDose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | sin fecha |
| Completado | no aplica | A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple SclerosisEsclerosis multiple | sin fecha |